Aflibercept Treatment with Fluoropyrimidine and Irinotecan Starting before radical surgery in patients with Resistant rectal cancer failing to respond or showing disease progression according to magnetic resonance imaging (MRI) criteria at a six weeks assessment after completion of treatment with neoadjuvant chemoradiation to downstage and facilitate a curative resection.
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 29 Oct 2014
Price : $35 *
At a glance
- Drugs Aflibercept (Primary) ; Irinotecan (Primary) ; Fluoropyrimidine derivatives
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms AT FIRST
- 25 Oct 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by United Kingdom Clinical Research Network record.
- 11 Jul 2014 New trial record